Bio:

Education

• B.A. (Wharton)
• D. in Molecular Biology (SUNY@ Stony Brook)
• S. in Biology (Fudan University)

Experience

1. Partner

6 Dimensional Capital

• Lead cross-border equity investments in life science innovations
• Sourced and lead 8 investments in the US, EU and China

2. Managing Director, Head of International Investments and Business Development, Humanwell Healthcare Group 2013 - 2016

• Led $550M acquisition of a US specialty pharma, the largest cross border M&A deal by a Chinese healthcare company
• Leading the strategy, investment and business development in ex-China markets; Helping this $3B market cap firm further grow its $1.2B/year revenue (38.6% CAGR since 2006); Driving Humanwell into a global company in human health and wellness industry
• Bringing high quality assets/platforms into China market: screened over 4000 deals in 37 months; completed two M&A deals, two drug in-licensing deals, and three product distribution deals; Over eight live deals in late stage discussion
• Investing in developed and emerging markets for equity ownership
• In discussion with Gates Foundation and one MNC pharma for strategic partnership 
 Managing Director, China, Burrill Life Science VC Fund 2011 - 2012
• Spearhead VC investments in emerging markets with Company’s $1.5B AUM
• Fundraising for Burrill-Fosun Healthcare Venture Fund
• Fostered technology and market innovations in China healthcare industry, through 
long term collaboration between Fosun Pharma and Burrill & Co (>160 combined deal flow per month) 
 Vice President, Portfolio Manager/Analyst (Franklin Templeton Inv.) 2004 - 2011
• Invested in life science sector with bottom- up fundamental analysis; Invested global 
life science firms; Performance ranked top quartile among over 40 analysts in the 
department
• Co- managed the Franklin Biotech Discovery Fund; Ranked top quartile in 1 and 5 
year periods; Selected “winners”: Pharmacyclics: 317%; Pharmion: 374%; Celgene: 
171%; Genentech: 219%; Onyx: 461%; OSI: 162%; Threshold: 234%
• Invested in Chinese healthcare firms such as 3S Bio (in Shenyang, 107% return), 
Minray Medical (Shengzhen, 239%), BMP Sunstone (Beijing, 197%), Omnitura

(Private, Shengzhen); Screened and analyzed > 60 Chinese private and public life

science firms
• Advised Chinese entrepreneurs on business development and financial management

5. Vice President of Business Development (Genyous Life Sciences) 2003 - 2004

• Conducted due diligence, market research, strategic planning, and out- / in- licensing 
deal sourcing for the biotech startup
• Raised $23M through equity financing and partnership 
 Investment Associate (BioAdvance) 2002 - 2003
• Established process for deal sourcing, triage, and due diligence on early stage life 
science startups for venture capital investment
• Built operational and financial models to assess and mitigate investment risks.
• Invested in GelFlex (Acquired by Synthe), Alteris Therapeutics (Acquired by 
Celldex), and Acuity Pharma (Merged WITH Opko Health) 
 Director of Life Science Investing (Acacia Research Co.) 2000 - 2002
• Screened > 40 therapeutics, diagnostics, medical device and healthcare service 
companies for venture investment opportunities
• Designed deal structures, prepared term sheets and negotiated terms. Prepared 
investment memorandums.
• Analyzed life science stocks for PIPE, RD, or open market investing 
 Irvington Research Fellow (Skirball Institute) 1997-1999
• Conducted bench-top research on AIDS and immunological diseases
• Licensed proprietary technology to Millennium Pharmaceuticals for milestone and 
royalty payments
8. Research Associate (Shanghai Biological Product Inc.) 1990 – 1992
• Developed and marketed HIV diagnostic kits with synthetic antigen in China Board Membership

1. Board member, LDX Prognostic Company

Honors/Awards

1.Recipient of 3551 Talent Program in Hubei, China

2.Graduate Council Commendation to Outstanding Doctoral Students

3.Sigma Xi Chapter Award

4.Abrahams Award for Outstanding Scientific Achievement

5. Co-author of a scientific paper at Science Magazine and a dozen first author papers

Membership

1.Advisor, Stanford Spark Translational Research Program

2.Founding member of Chinese executive network BayHelix Group

3.Member of Chinese-American BioPharmaceutical Society (CABS)

4.Member of Sino-American Pharmaceutical Association (SAPA)

Fluent in both Chinese and English